NCT03131700撤回1 期
Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- TRPHARM
- 主要终点
- Area under concentration-time curve from time zero to the last sampling time
研究概览
简要总结
The purpose of this to assess pharmacokinetic bioequivalence between two bevacizumab products, RPH-001 (TRPHARM) and EU sourced Avastin® (Roche), after single IV administration at 5 mg/kg fixed dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects aged 18 to 55 years inclusive.
- •Adult healthy male subjects between 18.0 and 30.0 kg/m2 body mass index (inclusive) and body weight ≥ 60 kg and ≤ 100 kg (inclusive).
排除标准
- •Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
- •Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).
- •Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
- •Positive alcohol test at screening or baseline visits
结局指标
主要结局
Area under concentration-time curve from time zero to the last sampling time
时间窗: Until 100 days after administration
Area Under the Curve - AUC(0-t)
Area under concentration-time curve from time zero to infinity
时间窗: Until 100 days after administration
Area Under the Curve - AUC(0-∞)
Maximum plasma concentration
时间窗: Until 100 days after administration
Cmax
次要结局
- Physical examination(Until 100 days after administration)
- Concentration-time profiles(Until 100 days after administration)
- Terminal elimination rate constant (λz)(Until 100 days after administration)
- Nature, frequency, severity and relationship to study drug of recorded adverse events(Until 100 days after administration)
- Heart rate(Until 100 days after administration)
- Body temperature(Until 100 days after administration)
- Neutralizing antibody (NAb)(Until 100 days after administration)
- Respiratory rate(Until 100 days after administration)
- Terminal elimination half-life (t½)(Until 100 days after administration)
- Volume of distribution at steady state (Vss)(Until 100 days after administration)
- Time to maximum concentration (Tmax)(Until 100 days after administration)
- ECG(Until 100 days after administration)
- Anti-drug-antibody (ADA)(Until 100 days after administration)
- Apparent volume of distribution (Vz)(Until 100 days after administration)
- Clearance (CL)(Until 100 days after administration)
- Blood Pressure(Until 100 days after administration)
- Oxygen saturation(Until 100 days after administration)
- Clinical laboratory tests(Until 100 days after administration)
研究者
相似试验
已完成
1 期
Study of Bevacizumab With Different Manufacturing Process in Healthy Male SubjectsHealthy Male SubjectsNCT05005455Innovent Biologics (Suzhou) Co. Ltd.100
Unknown
1 期
PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)HealthyNCT02747823Cipla BioTec Pvt. Ltd.150
招募中
2 期
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerPlatinum-resistant Ovarian CancerOvarian CancerNCT04787289British Columbia Cancer Agency244
已完成
2 期
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 MeningiomaAnaplastic (Malignant) MeningiomaAtypical MeningiomaGrade II MeningiomaGrade III MeningiomaRecurrent MeningiomaSupratentorial MeningiomaNCT02847559Northwestern University20
已完成
3 期
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung CancerEfficacyNCT05427305TOT Biopharm Co., Ltd.549